Invention Grant
US08529901B2 Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label 有权
结合肿瘤抗原的第一非标记单克隆抗体和用NIR荧光标记标记的非交叉反应性第二单克隆抗体的组成

  • Patent Title: Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
  • Patent Title (中): 结合肿瘤抗原的第一非标记单克隆抗体和用NIR荧光标记标记的非交叉反应性第二单克隆抗体的组成
  • Application No.: US12599713
    Application Date: 2008-06-04
  • Publication No.: US08529901B2
    Publication Date: 2013-09-10
  • Inventor: Max HasmannHelmut LenzWerner Scheuer
  • Applicant: Max HasmannHelmut LenzWerner Scheuer
  • Applicant Address: US NJ Nutley
  • Assignee: Hoffmann-La Roche, Inc.
  • Current Assignee: Hoffmann-La Roche, Inc.
  • Current Assignee Address: US NJ Nutley
  • Priority: EP07011087 20070606
  • International Application: PCT/EP2008/004456 WO 20080604
  • International Announcement: WO2008/148546 WO 20081211
  • Main IPC: A61K39/395
  • IPC: A61K39/395
Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
Abstract:
This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.
Information query
Patent Agency Ranking
0/0